Advertisement

Topics

A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g

2010-07-15 17:00:00 | BioPortfolio

Summary

This is a Phase IIb, multicenter, open-label study available to active (Xolair) and control (placebo) subjects who have completed their final visit (or early termination visit, if applicable) for Study Q2788g, who meet the eligibility criteria of this study, and who provide consent to participate in this study.

Study Design

Control: Uncontrolled, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Peanut Hypersensitivity

Intervention

omalizumab

Status

Completed

Source

Genentech

Results (where available)

View Results

Links

Published on BioPortfolio: 2010-07-15T17:00:00-0400

Clinical Trials [255 Associated Clinical Trials listed on BioPortfolio]

A Safety and Efficacy Study of Xolair in Peanut Allergy

This is a 38-week, randomized, double-blind, placebo-controlled, parallel group trial of approximately 150 patients who have a history of immediate hypersensitivity reaction to peanut prot...

Peanut Oral Immunotherapy

This is a study in which increasing amounts of peanut flour are given to the children who are peanut allergic to desensitize them to peanut. The hypothesis is that the peanut allergic pati...

Peanut Sublingual Immunotherapy

The purpose of this study is to evaluate the safety and immune response to daily sublingual (under the tongue) immunotherapy (SLIT) with peanut extract in adults and children with peanut a...

Mucosal Immunotherapy for Peanut Allergy in Young Children

Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit young subjects who have recently been diagnosed wi...

Oral Immunotherapy (OIT) for Peanut Allergy

Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit subjects who have peanut allergy by lowering the r...

PubMed Articles [408 Associated PubMed Articles listed on BioPortfolio]

Long-term Outcome of Peanut Oral Immunotherapy Facilitated Initially by Omalizumab.

We successfully used omalizumab to faciliate peanut oral immunotherapy (OIT) in children with reactivity to ≤50mg peanut protein and with high peanut-IgE (median 229 kU/L).

Omalizumab in Chronic Urticaria: An Italian Survey.

Omalizumab is approved for use in chronic spontaneous urticaria (CSU); however, it is not approved for chronic inducible urticaria (CIndU). The aim of the present study was to assess the effectiveness...

Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial.

Omalizumab has demonstrated therapeutic benefits both in controlled clinical trials and real-life studies. However, research concerning the long-term effects and tolerability of omalizumab is needed. ...

Omalizumab treatment in a 12 year-old girl with chronic spontaneous urticaria.

Omalizumab is a recombinant humanized IgG monoclonal antibody, which binds the Fc region of free IgE prevent its binding to its high-affinity receptor (FcεR1) on mast cells and basophils. Omalizumab ...

Omalizumab in Chronic Spontaneous Urticaria: steroid sparing effect.

Omalizumab has been recognized to be effective in the treatment of chronic spontaneous urticaria (CSU). The Italian Medicines Agency authorizes two omalizumab courses, only for patients with CSU unres...

Medical and Biotech [MESH] Definitions

Allergic reaction to peanuts that is triggered by the immune system.

Allergic reaction to tree nuts and peanuts, including other LEGUMES, that is triggered by the immune system. It includes co-sensitization to other food (e.g., sesame seed).

Allergic reaction to products containing processed natural rubber latex such as rubber gloves, condoms, catheters, dental dams, balloons, and sporting equipment. Both T-cell mediated (HYPERSENSITIVITY, DELAYED) and IgE antibody-mediated (HYPERSENSITIVITY, IMMEDIATE) allergic responses are possible. Delayed hypersensitivity results from exposure to antioxidants present in the rubber; immediate hypersensitivity results from exposure to a latex protein.

Antigen-type substances that produce immediate hypersensitivity (HYPERSENSITIVITY, IMMEDIATE).

Oil derived from PEANUTS.

More From BioPortfolio on "A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial